Boston Scientific BSX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.34B+99.9% | $670M-11.3% | $755M-5.0% | $795M+18.3% | $672M+19.6% | ||
| $351M-3.8% | $365M+6.7% | $342M+1.8% | $336M+3.4% | $325M-6.6% | ||
| $83M+16.9% | $71M-10.1% | $79M+5.3% | $75M+1.4% | $74M+7.2% | ||
| $117M+19.4% | $98M+206% | $32M0.0% | $32M-70.1% | $107M+18.9% | ||
| $177M+254% | $50M-46.8% | $94M— | —— | $109M— | ||
| -$512M-280% | $285M+72.7% | $165M-28.6% | $231M+160% | -$385M-200% | ||
| $27M+35.0% | $20M— | —— | $79M+1,229% | -$7M-170% | ||
| $348M-74.5% | $1.36B+1.6% | $1.34B+4.4% | $1.29B+138% | $541M-62.8% | ||
| $177M-49.6% | $351M+93.9% | $181M+15.3% | $157M-16.0% | $187M-32.5% | ||
| $523M+488% | $89M-65.2% | $256M-74.6% | $1.01B+322% | $239M-93.0% | ||
| -$591M-15.4% | -$512M-2.0% | -$502M+55.4% | -$1.13B-125% | -$500M+86.5% | ||
| -$260M-41.3% | -$184M-76.9% | -$104M+69.4% | -$340M-246% | $233M+8.9% | ||
| $0-100% | $3M— | $0-100% | $2M-94.9% | $39M+533% | ||
| -$504M-175% | $671M-8.7% | $735M— | —— | $314M+115% | ||
| —— | $79.75M0.0% | $79.75M0.0% | $79.75M0.0% | $79.75M+27.6% | ||
| —— | $140.25M0.0% | $140.25M0.0% | $140.25M0.0% | $140.25M-14.5% | ||
| -$30M-529% | $7M-36.4% | $11M+320% | -$5M-200% | $5M+600% | ||
| -$351M-1,495% | -$22M-132% | $69M+177% | -$90M-320% | $41M+151% | ||
| $158M— | —— | —— | $219M+882% | -$28M-47.4% | ||
| $109M— | —— | —— | $31M-59.7% | $77M+353% | ||
| $2M-60.0% | $5M-44.4% | $9M-75.7% | $37M-54.3% | $81M+58.8% | ||
| -$48M+34.2% | -$73M-1,725% | -$4M0.0% | -$4M-33.3% | -$3M+50.0% | ||
| -$61M-182% | $74M+5.7% | $70M+112% | $33M-57.1% | $77M+381% | ||
| $0-100% | $209M+2,886% | $7M+16.7% | $6M-83.3% | $36M— | ||
| $85M+2,733% | $3M-40.0% | $5M0.0% | $5M-95.8% | $118M+2,850% | ||
| $0— | —— | —— | —— | $1.56B— | ||
| $3M-66.7% | $9M+1,000% | -$1M-111% | $9M+190% | -$10M-3,900% | ||
| $0— | —— | —— | —— | -$192M-203% | ||
| $81M+305% | $20M-82.6% | $115M+259% | $32M-72.2% | $115M+311% | ||
| $259M— | $0-100% | $12M-97.6% | $500M-53.8% | $1.08B— | ||
| —— | $29.75M0.0% | $29.75M0.0% | $29.75M0.0% | $29.75M+1.7% | ||
| $171M-83.1% | $1.01B-12.8% | $1.16B+2.9% | $1.13B+219% | $354M-70.0% | ||
| $171M-83.1% | $1.01B-12.8% | $1.16B+2.9% | $1.13B+219% | $354M-70.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Boston Scientific generate?
- Boston Scientific (BSX) generated $4.3B in operating cash flow over the trailing twelve months.
- What is Boston Scientific's free cash flow?
- After $866.0M of capital expenditures, Boston Scientific's free cash flow was $3.5B over the trailing twelve months, up 15.3% year over year.
- Where does Boston Scientific's cash flow data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
